On-the-road driving performance of patients with central disorders of hypersomnolence - van der Sluiszen NNJJM, Urbanus B, Lammers GJ, Overeem S, Ramaekers JG, Vermeeren A.
INTRODUCTION: Excessive Daytime Sleepiness is a core symptom of narcolepsy and idiopathic hypersomnia, which impairs driving performance. Adequate treatment improves daytime alertness, but it is unclear whether driving performance completely normalizes. Th... (Source: SafetyLit)
Source: SafetyLit - February 8, 2021 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
How the brain paralyzes you while you sleep
(University of Tsukuba) Researchers from the University of Tsukuba have discovered a group of neurons in the mouse brainstem that control muscle tone. Inhibiting these neuronal cells caused mice to move during REM sleep, reminiscent of REM sleep behavior disorders. These neurons were also responsible for episodes of cataplexy in a mouse model of narcolepsy; inhibiting them reduced the number of cataplexic bouts. These circuits could thus be a new target for treating these sleep disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 14, 2021 Category: International Medicine & Public Health Source Type: news
Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix(R) (pitolisant)
Citrine was founded by Eight Roads, F-Prime Capital, and Vivo Capital; and closed an $80 Million Series A financing earlier this year
Company is focused on bringing important rare disease therapies to China while accelerating the rare disease drug devel... Biopharmaceuticals, Licensing Citrine Medicine, Bioprojet, Wakix, pitolisant, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 28, 2020 Category: Pharmaceuticals Source Type: news
Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX(R) (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy
WAKIX is the first and only non-scheduled treatment approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy
PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Harmony Bioscienc... Biopharmaceuticals, FDA Harmony Biosciences, WAKIX, pitolisant, cataplexy, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 14, 2020 Category: Pharmaceuticals Source Type: news
Harmony Biosciences Receives FDA Approval for Expanded Use of Wakix (pitolisant) for the Treatment Of Cataplexy in Adult Patients with Narcolepsy
PLYMOUTH MEETING, PA and CHICAGO, IL, October 13, 2020— Harmony Biosciences Holdings, Inc. ( " Harmony " ) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 13, 2020 Category: Drugs & Pharmacology Source Type: news
Depression and suicidal thoughts in untreated and treated narcolepsy: systematic analysis - Barateau L, Lopez R, Chenini S, Pesenti C, Rassu AL, Jaussent I, Dauvilliers Y.
OBJECTIVES: To assess the frequency and determinants of depressive symptoms and suicidal thoughts in adults with narcolepsy type 1 (NT1) and controls, as well as the changes after NT1 management, and the risk factors of major depressive episode (MDE) and s... (Source: SafetyLit)
Source: SafetyLit - September 25, 2020 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Narcolepsy Drug Doesn't Raise Odds for Birth Defects: Study
This study is based on twice as many pregnancies as earlier studies, and we... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 4, 2020 Category: General Medicine Source Type: news
Narcolepsy drug did not increase risk of fetal malformation
(Karolinska Institutet) Modafinil is used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant. Now, a large registry study involving over two million pregnant women in Sweden and Norway shows that there is no such association. The study, which is published in JAMA, was conducted by researchers at Sweden's Karolinska Institutet and the Norwegian Institute of Public Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2020 Category: International Medicine & Public Health Source Type: news
'Pay-for-delay' plan blocked cheap generic challengers to Peninsula company's narcolepsy drug for years, lawsuits claim
Legal maneuvering by the company effectively blocked a generic drug for narcolepsy from entering the market since 2011. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 12, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
'Pay-for-delay' plan blocked cheap generic challengers to Peninsula company's narcolepsy drug for years, lawsuits claim
Legal maneuvering by the company effectively blocked a generic drug for narcolepsy from entering the market since 2011. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 12, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Can a peer support the process of self-management in narcolepsy? A qualitative narrative analysis of a narcoleptic patient - Franceschini C, Fante C, Filardi M, Folli MC, Brazzi F, Pizza F, D'Anselmo A, Ingravallo F, Antelmi E, Plazzi G.
INTRODUCTION: Narcolepsy type 1 (NT1) is a chronic and rare sleep disorder typically arising during adolescence and young adulthood. The main symptoms are excessive daytime sleepiness and cataplexy, a prototypical fall down elicited by huge emotions. Socia... (Source: SafetyLit)
Source: SafetyLit - August 3, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
FDA Okays Low-Sodium Treatment Option for Narcolepsy FDA Okays Low-Sodium Treatment Option for Narcolepsy
The novel drug Xywav is an oxybate product with a unique composition that results in 92% less sodium than sodium oxybate (Zyrem).FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 22, 2020 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years
Xywav contains 92 percent less sodium per nightly dose than sodium oxybate, a curre... Biopharmaceuticals, Neurology, FDA Jazz Pharmaceuticals, Xywav, Cataplexy, Narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 22, 2020 Category: Pharmaceuticals Source Type: news
Jazz Pharmaceuticals expands sleep disorder drug portfolio with FDA approval of Xywav
The Food and Drug Administration has approved Jazz Pharmaceuticals' new drug application for Xywav, a new sleep disorder drug.
Xywav was approved by the FDA, Tuesday night, to treat cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Jazz stock was up nearly 4.6% to $110.34 per share in early morning trading.
Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. People with narcolepsy often… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 22, 2020 Category: Biotechnology Authors: John George Source Type: news
FDA Approves Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
DUBLIN, July 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 22, 2020 Category: Drugs & Pharmacology Source Type: news
